Consolidated Statements of Comprehensive Loss - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Jun. 30, 2016 |
Jun. 30, 2015 |
Jun. 30, 2016 |
Jun. 30, 2015 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Operating costs and expenses: | ||||||
| Research and development | $ (2,205,213) | $ (555,740) | $ (2,634,494) | $ (1,590,823) | $ (3,434,016) | $ (6,323,896) |
| IPR&D expense | (39,500,000) | 0 | (39,500,000) | 0 | 0 | 0 |
| General and administrative | (1,557,677) | (803,399) | (2,980,043) | (1,738,625) | (6,388,000) | (6,600,870) |
| Loss from operations | (43,262,890) | (1,359,139) | (45,114,537) | (3,329,448) | (9,822,016) | (12,924,766) |
| Other income (expense): | ||||||
| Change in fair value of derviative liability | 1,769,275 | 0 | 1,905,289 | 0 | (2,125,117) | 0 |
| Loss on issuance of hybrid debt instrument | 0 | 0 | (1,584,218) | 0 | (59,612) | 0 |
| Loss on disposal of subsidiaries | 0 | (1,069,675) | ||||
| Loss on conversion of debt | (6,187,337) | 0 | (6,187,337) | 0 | ||
| Other income (expense) | 12,863 | 234,453 | (13,551) | (225,515) | (295,033) | (326,916) |
| Interest income | 13 | 914 | 27 | 1,088 | 1,694 | 18,959 |
| Interest expense | (103,086) | (1,386) | (348,470) | (2,512) | (266,999) | (4,706) |
| Total other income (expense) | (4,508,272) | 233,981 | (6,228,260) | (226,939) | (2,685,455) | (1,382,338) |
| Net loss | (47,771,162) | (1,125,158) | (51,342,797) | (3,556,387) | (12,507,471) | (14,307,104) |
| Other comprehensive income (loss) | ||||||
| Other comprehensive loss from foreign currency translation adjustment | 0 | (338,875) | 0 | (327,054) | (321,942) | (324,578) |
| Total comprehensive loss | $ (47,771,162) | $ (1,464,033) | $ (51,342,797) | $ (3,883,441) | $ (12,829,413) | $ (14,631,682) |
| Net loss per share of common stock, basic and diluted | $ (6.12) | $ (.27) | $ (8.28) | $ (.84) | $ (.09) | $ (.11) |
| Weighted-average shares of common stock outstanding, basic and diluted | 7,804,187 | 4,221,328 | 6,197,776 | 4,221,328 | 140,397,488 | 135,896,022 |
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. No definition available.
|
| X | ||||||||||
- Definition Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries or equity method investee. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of interest income earned from interest bearing assets classified as other. No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|
| X | ||||||||||
- Definition Loss on issuance of hybrid debt instrument No definition available.
|